GlassScriptPhysician profile
Andrew D Conkle
NPI 1639132129
$2,654.94
in general payments reported to CMS, 2019-2025
22 companies · $584 in 2025
The $584 reported for 2025 was more than what 83% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $185 · 2022: $376 · 2023: $531 · 2024: $978 · 2025: $584.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,094.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,094.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $359.16 | 2021-2024 | Lifevest |
| Amgen INC. | $348.67 | 2021-2024 | Repatha |
| Astrazeneca Pharmaceuticals LP | $335.27 | 2021-2025 | Farxiga, Wainua |
| Dexcom, INC. | $325.96 | 2022-2024 | Dexcom G7 Gss (161) |
| Novo Nordisk INC | $226.84 | 2023-2025 | Wegovy, Ozempic |
| Novartis Pharmaceuticals Corporation | $154.90 | 2021-2025 | |
| Abiomed | $145.06 | 2024-2025 | Impella |
| Pfizer INC. | $144.47 | 2024-2025 | |
| Edwards Lifesciences Corporation | $139.07 | 2023-2025 | Sapien 3 Ultra Resilia, Mitris Resilia Mitral Valve, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Alexion Pharmaceuticals, INC. | $120.83 | 2023 | |
| Janssen Pharmaceuticals, INC | $58.69 | 2022-2024 | Xarelto |
| Chiesi USA, INC. | $51.86 | 2024-2025 | Kengreal |
| Boston Scientific Corporation | $50.47 | 2022-2025 | Watchman Flx |
| Haemonetics Corporation | $32.42 | 2023 | Teg6s Hemostasis System |
| Esperion Therapeutics, INC. | $30.39 | 2024-2025 | Nexletol |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.23 | 2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $22.15 | 2025 | |
| Atricure, INC. | $20.47 | 2024 | |
| Kiniksa Pharmaceuticals, LTD. | $19.65 | 2023 | Arcalyst |
| Ethicon US, LLC | $18.37 | 2024 | Endopath Xcel |
| Lexicon Pharmaceuticals, INC. | $15.27 | 2023 | Inpefa |
| Teleflex LLC | $11.74 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Conkle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.